A patient-first mindset for change

May marks World Clinical Trials Day, bringing awareness to trials and the vital role they play in understanding, diagnosing, treating, and preventing diseases.

Today, clinical trials, whether decentralised, hybrid, or site-based are facing a common challenge: increasing complexity without a corresponding improvement in execution.

An outdated operational model

Over the past decade, protocols have become more demanding, patient expectations have evolved, and global studies have expanded in scale and scope. While innovation has accelerated, the operational model underpinning trials has struggled to keep pace.

One of the most persistent issues is fragmentation. Many trials rely on multiple disconnected technologies, each designed to solve a specific problem, but rarely integrated into a cohesive ecosystem. This creates friction for all stakeholders. Patients are often required to navigate multiple devices or applications, clinical sites are burdened with managing parallel systems, and sponsors face challenges in maintaining consistent oversight across fragmented data streams. The result is inefficiency, increased risk of error and, ultimately, a poor experience for both patients and investigators.

Alongside this, patient recruitment and retention remain critical pressure points. Despite advances in decentralised approaches, participation in trials can still be restrictive. Geographic limitations, time commitments, and the practical realities of day-to-day life continue to impact engagement. Even where remote technologies are deployed, they are not always implemented in a way that genuinely reduces burden. If participation feels complicated or intrusive, dropout rates remain a risk regardless of the underlying scientific merit of the study.

Another key issue is scalability. While many decentralised solutions have proven effective in pilot or smaller studies, translating those models into large, global trials introduces new challenges. Variability in infrastructure, connectivity, and regulatory environments can impact consistency. Without standardisation, what works well in one region may not translate seamlessly into another, creating operational inefficiencies and potential data variability.

A perspective shift to patient centricity

Underlying many of these challenges is a broader industry mindset that can, at times, slow progress. There is often a tendency to adopt new technologies in isolation, layering solutions onto existing processes, rather than rethinking the model as a whole. This incremental approach can lead to greater complexity, rather than meaningful improvement. In some cases, there is also a reliance on familiar, legacy approaches, driven by risk aversion in a highly regulated environment. While caution is understandable, it can limit the pace at which more effective, patient-centric models are adopted at scale.

Addressing these challenges requires a shift in perspective. Rather than focusing on individual tools or technologies, the industry must prioritise integration and simplicity. Clinical trials should be designed around the patient journey, not the constraints of infrastructure. This means creating environments where participation is intuitive, where technology supports, rather than disrupts, and where operational processes are streamlined across all stakeholders.

Purpose-built ecosystems will play a critical role in enabling this shift. Solutions designed specifically for clinical research, rather than adapted from consumer technologies can provide the consistency, control, and scalability required for global deployment. Standardisation of devices, connectivity, and data management can significantly reduce variability and improve execution.

Equally important is a more collaborative approach across sponsors, CROs, and technology providers. Greater alignment on standards, interoperability, and best practice will be essential in reducing fragmentation and unlocking the full potential of decentralised and hybrid models.

Ultimately, the future of clinical trials will not be defined by whether they are decentralised or site-based, but by how effectively they are executed. The organisations that succeed will be those that move beyond incremental change and embrace a more integrated, patient-first approach one that reduces complexity, improves accessibility, and delivers more reliable outcomes at scale.

About the author

Steve Sanghera is CEO and co-founder of Inventus. His extensive career spans over 20 years in mobile technology and financial solutions, including several senior roles with companies including Caudwell Group and Ikon Office Solutions. Sanghera also spent two years in an advisory role for the New York Stock Exchange focusing on the global mobile telecommunications industry. Over the last ten years, he has taken his previous learnings and channelled them into entrepreneurial activities, striving for a positive impact and creating change for the better.